Sildenafil Tablet, Film Coated
Product Images NDC 63629-7833

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 63629-7833). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636297833)

Label for Sildenafil Citrate 50 mg tablet, film coated, packaged by Bryant Ranch Prepack in Burbank, CA. The label indicates the product compares to Viagra 50 mg tablets by Amneal Pharmaceuticals Pvt Ltd. It includes storage instructions to keep at 20°-25°C (68°-77°F) and a warning to keep drugs out of reach of children. The label shows a quantity of 30 tablets and displays the NDC 63629-7833.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure diagram of the active ingredient Sildenafil, showing its molecular components and bonds.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

A line graph depicting systolic blood pressure changes (mmHg) over 24 hours post dose. Two lines compare Sildenafil 100 mg and placebo. The x-axis shows time post dose in hours, and the y-axis shows systolic blood pressure changes, illustrating variations between the Sildenafil and placebo groups.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph displaying the change in systolic blood pressure (SBP) in mmHg over time post dose in hours. It compares two groups: one receiving Doxazosin with placebo and the other Doxazosin with Sildenafil 25 mg. Both groups show a decrease in SBP within the first few hours followed by a gradual rise towards baseline by 8 hours.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

A line graph depicting change in systolic blood pressure (SBP) over 8 hours after dosing. It compares two groups: Doxazosin plus placebo and Doxazosin plus Sildenafil 50 mg, showing their SBP changes at various time points post-dose in hours.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

A line graph comparing the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with placebo over an 8-hour period. The y-axis measures blood pressure changes in mmHg, while the x-axis represents time after dosing in hours. Two lines depict changes for each combination treatment across the time points.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A line graph depicting plasma concentrations (ng/ml) over 24 hours post dose for a commercial tablet treatment. The x-axis shows time post dose in hours, and the y-axis shows plasma concentrations, illustrating the drug's concentration decline over time after administration.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

A bar chart depicting the effect of sildenafil on the maintenance of erection by baseline score. The x-axis shows the baseline score ranging from 0 to 5, and the y-axis represents the percentage of patients at the endpoint. Multiple bars per baseline score indicate different categories or response levels related to erection maintenance.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' depicting the percentage of patients at endpoint on the vertical axis and baseline scores from 0 to 5 on the horizontal axis. Different bars represent various categories labeled 0 to 5, illustrating varying patient percentages across baseline scores.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

A vertical bar chart showing the percentage of patients reporting improvement across four treatment groups: Placebo (24%), Sildenafil 25 mg (63%), Sildenafil 50 mg (74%), and Sildenafil 100 mg (82%). The x-axis represents the treatment groups, and the y-axis shows the percentage of patients reporting improvement from 0 to 100%. An overall treatment p-value is noted as less than 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.